Allegheny General Hospital
Pittsburgh, Pennsylvania, 15212, United States
NCT Number: NCT01347931
The Breathe NIOV™ System will reduce the work of breathing in subjects with chronic respiratory insufficiency who require long-term oxygen therapy (LTOT). The Breathe system will accomplish this by providing oxygen under pressure and augmenting the subject's spontaneous tidal volumes. The combination of efficient oxygen delivery, assisted ventilation, and a comfortable low-profile device, will result in a mean improvement in perceived well-being and ability to perform ADLs, as measured by patient-reported outcome (PRO) instruments.
Looking for future studies?
Notify Me21 year–80 year
All sexes
Interventional
Not applicable
Pittsburgh, Pennsylvania, 15212, United States
This will be a prospective, open-label, crossover study in up to 12 stable subjects with chronic respiratory insufficiency who require LTOT. Each subject's standard oxygen therapy will be used as the control treatment and compared to the test ventilator system during selected activities of daily living. Subjects will participate in the study for up to 9 home visits, with Visits 1 and 2 each lasting for approximately 4 hours, and Visits 3-9 lasting approximately 1-2 hours each. Subjects may discontinue study participation at any time.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Each subject's standard oxygen therapy will be used as the control treatment and compared to the test ventilator (NIOV) system during selected activities of daily living.
Other names: NIOV, Oxygen, O2
Supplemental oxygen via a standard oxygen cannula connected to a portable oxygen cylinder
Other names: Cannula
Time frame: Measured during single day study visit
Time in minutes of sustained activity while using test treatments
Time frame: Measured during activity testing in a single day study visit
O2 saturation measured by pulse oximetry
Time frame: Measured during activity testing in a single day study visit
Borg Dyspnea score is measured using a 11-point visual analog scale. The lower the score on the scale, the less breathlessness patient experiences. The score ranges from:
0 = No breathlessness at all, representing better outcome 10 = Maximum, representing worse outcome
Breathe Technologies, Inc.
Industry
In-home Evaluation of the Breathe Technologies Noninvasive Open Ventilation (NIOV™) System in Patients With Severe Respiratory Insufficiency
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01355978
Airflow Obstruction, Chronic, Chronic Disease
Concord, California, United States
View Trial DetailsNCT01495780
Behavior, Bronchial Diseases
Los Angeles, California, United States
View Trial DetailsNCT01033487
COPD, Chronic Disease
Berlin, Germany
View Trial DetailsNCT07252908
Chronic Disease, Disease Attributes
Chongqing, Chognqing, China
View Trial Details